Stay updated on Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page.

Latest updates to the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedLocations section reorganized with new abbreviations BS, FI, MI, and VA; removal of the BS/FI/MI/VA location subsections and upgrade from v3.3.2 to v3.3.3.SummaryDifference0.5%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedPage revision changed from v3.2.0 to v3.3.2; no study details or eligibility information were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedThe funding-status notice regarding government operations was removed; study details and contact information remain unchanged.SummaryDifference0.3%

- Check59 days agoChange DetectedNo significant differences detected between the two screenshots of the Study Details page for NCT03666325. Core sections such as Brief Summary, Design, Outcomes, Eligibility, Locations, and Contacts appear unchanged.SummaryDifference0.4%

- Check88 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference2%

- Check95 days agoChange DetectedUpdate to version v3.1.0 with new contact emails and phone numbers; removes the old version tag v3.0.2. No significant core content changes detected.SummaryDifference0.0%

Stay in the know with updates to Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page.